Genoptix/Novartis
On January 24, 2011, Genoptix, Inc. (Nasdaq: GXDX) announced hat it has entered into a definitive merger agreement to be acquired by Novartis (NYSE: NVS).
Under the agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25 per share, or total consideration of $470 million in equity and $330 million of enterprise value.
Closing is expected in H111.
Barclays Capital is serving as financial advisor to Genoptix and Cooley LLP is serving as Genoptix' legal advisor.
Under the agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25 per share, or total consideration of $470 million in equity and $330 million of enterprise value.
Closing is expected in H111.
Barclays Capital is serving as financial advisor to Genoptix and Cooley LLP is serving as Genoptix' legal advisor.
View Older Stories
-
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
-
Azenta Announces Nomination of Tina S. Nova, Ph.D. and Dorothy E. Puhy to Board of Directors
-
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications
-
Biocept (BIOC) Appoints Philippe Marchand as Chief Operating Officer
-
Biocept Appoints Philippe Marchand as Chief Operating Officer
-
Biocept (BIOC) Appoints Samuel D. Riccitelli as Interim CEO and President, Antonino Morales as Interim CFO
-
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
-
Epic Sciences Expands Leadership Team to Address Liquid Biopsy Demand
-
Biocept Names David Karlander as Senior Vice President of Commercial Operations
-
Infinity BiologiX Names Dr. Shareef Nahas as Vice President of Global Laboratory Operations and Clinical Services
-
Biocept (BIOC) Announces Samuel D. Riccitelli to Board
-
Biocept Appoints Samuel D. Riccitelli to its Board of Directors
-
Shasqi Announces Appointments of Wayne Saville, M.D., as Chief Medical Officer and Juan Jaen, Ph.D., as Member of Board of Directors
-
ORIC Pharmaceuticals Appoints Christian V. Kuhlen, M.D., as General Counsel
-
Exagen Inc. Expands Board of Directors with its Appointment of Chet Burrell, Tina Nova and Bruce Robertson
-
Exagen Inc. Expands Board of Directors with its Appointment of Chet Burrell, Tina Nova and Bruce Robertson
-
NeoGenomics (NEO), QIAGEN N.V. (QGEN) Collaboration to Offer Companion Diagnostic Test for HR+/HER2 for Advanced Breast Cancer Patients
-
NeoGenomics and QIAGEN Collaborate to Offer Companion Diagnostic Test for HR+/HER2 - Advanced Breast Cancer Patients to Detect a PIK3CA Mutation
-
Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna®(nilotinib)
-
Synthorx Expands Leadership Team with Three Key Hires
-
MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
-
OrthoPediatrics (KIDS) Appoints Samuel Riccitelli to its Board of Directors
-
OrthoPediatrics Corp. Appoints Samuel D. Riccitelli to its Board of Directors
-
Tandem Diabetes (TNDM) Reports Leigh Vosseller to Succeed John Cajigas as CFO
-
Tandem Diabetes Care Announces Retirement of CFO and Successor Appointment
-
Quadax Inc. Appoints Walt Williams as Director of Revenue Cycle Optimization & Strategy
-
Genoptix and Bionano Genomics Announce Strategic Alliance
-
OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors
-
Aerie Pharmaceuticals Announces Expansion of Commercialization Team
-
NanoString Technologies (NSTG) Highlights Validation of to Expand Business Communications Offerings in Sweden at AACR Meeting, 4/1-4/5
-
Digital Spatial Profiling Technology Enables Quantitative Protein Profiling in FFPE Tissue Providing Detailed Molecular Characterization of Immune Response to Tumors
-
Ampersand Capital Partners and 1315 Capital Close Transaction to Acquire Genoptix
-
Ampersand Capital Partners and 1315 Capital to Acquire Genoptix
-
Synthetic Genomics Appoints Tina Nova, Ph.D., and William McKee to Board of Directors
-
Mastering Change Management in an Era of Unprecedented Market Volatility Captures the Conversation at HMG Strategy's Upcoming 2016 San Diego CIO Executive Leadership Summit
-
Ignyta Appoints Dr. Christian V. Kuhlen as General Counsel
-
Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
-
Tandem Diabetes Care Expands Commercial Leadership
-
MEI Pharma (MEIP) Appoints New Board Chair
-
MEI Pharma Appoints Dr. Christine White as Chairman of the Board
-
Veracyte Names Tina S. Nova, Ph.D. to Its Board of Directors
-
GenomeDx Biosciences Adds Tina Nova and Craig Johnson to Board of Directors
-
Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory Affairs and Wayne Saville, M.D., as Vice President of Clinical Oncology
-
S&P Announces Changes to US Indices: (NCI) for (GXDX) in SmallCap 600, (NOG) for NCI in MidCap 400
-
Unusual 11 Mid-Day Movers 01/24: CLDA, OCCF, NVGN, SSCC, RNN, GXDX Higher; APP, WHX, RSH, ONSM, GENE Lower
-
This Hedge Fund Guru Profited Big-Time From the Buyout of Genoptix (GXDX), See What Other Targets He Is Buying
-
Notable Mergers and Acquisitions of the Day 01/24: RKT/SSCC, NVS/GXDX, GE, HTGC
-
Morning Movers 01/24: CLDA, NVGN, SSCC, GXDX, OCCF, RNN, CWST, SILC, PSTI Higher; RSH, GENE, SRX, OVTI Lower

